On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s anti-PD-L1 antibody durvalumab (Imfinzi®) in combination with Bacillus Calmette-Guerin (BCG) intravesical therapy for adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). This is the first immunotherapy combination regimen approved for NMIBC—a historic approval that establishes the paradigm of pairing a modern checkpoint inhibitor with BCG, the 50-year-old standard of care for bladder cancer. This article summarizes the pivotal POTOMAC trial design, key efficacy data, safety profile, and regulatory and clinical significance.
Patient Population
- Adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC)
- High-risk NMIBC definition (POTOMAC criteria): post-TURBT patients meeting any of:
- T1 tumor
- Grade 3 (high-grade) tumor
- Carcinoma in situ (CIS)
- Multiple, recurrent, large tumors
- BCG-experienced or BCG-unresponsive patients are outside this approval’s scope (separately, pembrolizumab, nogapendekin alfa, nadofaragene firadenovec are approved for those settings)
Pivotal Trial Overview
The approval is based on data from the Phase 3 POTOMAC trial (NCT03528694), a multicenter, randomized, open-label study that enrolled 1,018 patients with high-risk NMIBC post-TURBT, in a three-arm comparative design.
| Item | POTOMAC Trial |
|---|---|
| Trial ID | NCT03528694 |
| Design | Randomized, open-label, multicenter, Phase 3 |
| N | 1,018 |
| Population | BCG-naïve high-risk NMIBC, post-TURBT |
| Intervention arm (approved regimen) | durvalumab 1500 mg q4w × 13 cycles + BCG induction and maintenance |
| Control arm | BCG induction and maintenance alone |
| Primary endpoint | Disease-free survival (DFS) |
| Key secondary endpoints | Overall survival (OS), time to progression, safety, patient-reported outcomes |
Durvalumab is an IgG1κ human monoclonal antibody that blocks PD-L1 on tumor cells from interacting with PD-1/CD80 on immune cells, restoring and enhancing T cell–mediated antitumor immunity. It has been approved in advanced NSCLC (post-chemoradiation maintenance in stage III), extensive-stage SCLC (ES-SCLC), hepatocellular carcinoma, biliary tract cancer, and endometrial cancer.
BCG intravesical therapy was introduced for bladder cancer in 1976 and remains the 50-year-old standard of care—the first-line local immunotherapy for non-muscle invasive bladder cancer. BCG is attenuated Mycobacterium tuberculosis that activates innate and adaptive immunity locally by direct mucosal contact, eliminating tumor cells. While BCG significantly reduces recurrence and progression risk in high-risk NMIBC, about 30–40% of patients still recur or progress within 5 years—a major unmet need. POTOMAC was the first large Phase 3 trial to combine systemic checkpoint inhibition with BCG local immunotherapy, directly addressing this gap.
Key Efficacy Results
| Endpoint | Durvalumab + BCG | BCG alone | HR / p-value |
|---|---|---|---|
| Disease-free survival (DFS) | Significant improvement | — | HR 0.68, 95% CI 0.50–0.93, p = 0.0154 |
POTOMAC met its primary DFS endpoint. Durvalumab + BCG demonstrated HR 0.68 vs BCG alone—a 32% reduction in the risk of recurrence, progression, or death (95% CI 0.50–0.93, p = 0.0154). The 95% confidence interval upper bound is clearly below 1.0, and the p-value confidently clears statistical significance. With a sample of 1,018, the result is highly robust.
The DFS improvement carries meaningful clinical implication for the “30–40% recurrence/progression” patients left behind by BCG monotherapy. In NMIBC, recurrence and progression are tied directly to (1) patient quality of life (repeated TURBT, repeat BCG instillations), (2) need for radical cystectomy, and (3) prognosis-worsening progression to muscle-invasive bladder cancer (MIBC). HR 0.68 brings benefit across all these axes.
OS data remain immature but trend in the same direction; the final analysis after sufficient event accumulation will be a key future watchpoint.
Safety Profile
The safety profile of durvalumab + BCG combines the toxicities of BCG monotherapy with the immune-related adverse events (irAEs) of PD-L1 blockade. Key management priorities include:
- BCG-related events—bladder irritation symptoms, hematuria, cystitis, fever, rarely disseminated BCG infection (BCG sepsis)
- Immune-related adverse events (irAEs)—interstitial pneumonitis, colitis, hepatitis, endocrinopathies (thyroid dysfunction, adrenal insufficiency), skin toxicity, rarely myocarditis
- Infusion reactions—during durvalumab infusion, mostly mild to moderate
- Compounded urologic toxicity—bladder irritation and hematuria frequencies tend to increase versus BCG alone
| Adverse Event | All Grades | Grade ≥3 |
|---|---|---|
| Bladder irritation (frequency, urgency) | ~50% | ~5% |
| Hematuria | ~35% | ~3% |
| Fatigue | ~30% | ~3% |
| Immune-mediated pneumonitis | ~5% | ~2% |
| Immune-mediated colitis | ~4% | ~2% |
| Immune-mediated endocrinopathy | ~8% | ~1% |
Because NMIBC has a relatively favorable prognosis (>80% 5-year survival), Grade ≥ 3 irAEs warrant careful risk-benefit evaluation. Patient selection (autoimmune history, active infection, steroid use) takes on greater importance than in advanced cancer settings.
Regulatory Significance and Clinical Positioning
The significance of this approval can be summarized along three axes.
(1) First immunotherapy combination regimen in NMIBC. Previous NMIBC immunotherapy approvals had been (a) BCG (local immunotherapy, 1976), (b) pembrolizumab monotherapy (BCG-unresponsive CIS, KEYNOTE-057, 2020), and others—all monotherapies or BCG alone. This approval establishes BCG + systemic PD-L1 inhibitor combination for the first time, pointing NMIBC drug development in a new direction. Expect acceleration of BCG combination trials for other checkpoint inhibitors (pembrolizumab, atezolizumab, nivolumab).
(2) Treatment intensification in the BCG-naïve setting. Recent new drug approvals have been centered on BCG-unresponsive / BCG-experienced settings (nogapendekin alfa, nadofaragene firadenovec, sacituzumab govitecan, etc.). This approval moves in the opposite direction—intensifying BCG in the BCG-naïve setting—a strategy of intervening earlier to prevent recurrence and progression. This contributes directly to two patient-critical outcomes: avoiding cystectomy and avoiding MIBC progression.
(3) Durvalumab’s expansion into urologic oncology. Durvalumab had previously been approved in NSCLC, SCLC, hepatobiliary cancers, and endometrial cancer; this approval extends it into urologic oncology. AstraZeneca is also developing durvalumab + tremelimumab in bladder cancer (NIAGARA, perioperative MIBC) and other programs in parallel, making this approval a key step in building the company’s bladder cancer franchise.
My Thoughts and Future Outlook
This is the first approval pairing a modern checkpoint inhibitor with BCG—the 50-year-old standard. DFS HR 0.68—a roughly 32% reduction in recurrence/progression risk—reshapes the NMIBC treatment landscape. The 30–40% of patients who recurred or progressed on BCG alone, previously moving to salvage cystectomy or newer agents like pembrolizumab, now have a path to earlier-stage intervention intensification. The patient QOL impact of avoiding cystectomy carries a different kind of weight from advanced cancer metrics.
However, NMIBC has a relatively favorable prognosis, so Grade ≥ 3 irAE situations of “losing a life to treatment toxicity” carry distinct ethical weight versus advanced cancer settings. Patient selection criteria (autoimmune history, prior corticosteroid use, active infection) and early irAE detection infrastructure (regular thyroid/liver/pulmonary monitoring) will determine safe deployment of this regimen in high-risk NMIBC. Coordination among urologists, medical oncologists, and endocrinologists will be foundational.
Next-wave developments include: (1) final OS analysis (whether recurrence/progression suppression translates to long-term survival), (2) BCG combination trial results for other checkpoint inhibitors (pembrolizumab, atezolizumab), (3) BCG dose/schedule optimization (standard induction + maintenance vs shorter regimens), (4) extension to intermediate/low-risk NMIBC, (5) biomarker (PD-L1 expression, TMB, tumor immune phenotype) correlation with efficacy. As the opening chapter of the immunotherapy combination era in NMIBC treatment, this approval will be remembered.
※This article is an independent summary by Morningglorysciences based on FDA approval documents, AstraZeneca press releases, and POTOMAC trial presentations. Treatment decisions should always reference the original publications, the latest prescribing information, and regional clinical guidelines.
Related Articles
- Oncology Drug Approval News Flash: FDA Approves Datopotamab Deruxtecan-dlnk (Datroway, Daiichi Sankyo/AstraZeneca) for 1L Unresectable or Metastatic TNBC (PD-(L)1 Ineligible)
- Oncology Drug Approval News Flash: FDA Approves Atezolizumab (Tecentriq, Genentech/Roche) for Adjuvant Treatment of Muscle-Invasive Bladder Cancer in Patients with Molecular Residual Disease
- Oncology Drug Approval News Flash: FDA Approves Pivekimab Sunirine-pvzy (Decnupaz, AbbVie) for Blastic Plasmacytoid Dendritic Cell Neoplasm
- Oncology Drug Approval News Flash: FDA Approves Zenocutuzumab-zbco (Bizengri, Merus N.V.) for Advanced, Unresectable or Metastatic Cholangiocarcinoma
- Oncology Drug Approval News Flash: FDA Approves Trastuzumab Deruxtecan (Enhertu, Daiichi Sankyo/AstraZeneca) for HER2-Positive Early Breast Cancer in Two Indications (Neoadjuvant and Adjuvant)
Comments